Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Read More…

Miscellaneous

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) announced its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.03. The biopharmaceutical company earned $3.14 million during the quarter, compared to the consensus estimate of $2.22 million. Verastem had a negative net margin of 526.42% and a negative return on equity of 118.53%. View Verastem's Earnings History.

When is Verastem's next earnings date?

What price target have analysts set for VSTM?

6 Wall Street analysts have issued 12-month target prices for Verastem's stock. Their forecasts range from $2.50 to $9.00. On average, they expect Verastem's share price to reach $5.75 in the next year. This suggests a possible upside of 329.1% from the stock's current price. View Analyst Price Targets for Verastem.

What is the consensus analysts' recommendation for Verastem?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verastem.

What are Wall Street analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:

1. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (7/13/2019)

Has Verastem been receiving favorable news coverage?

News headlines about VSTM stock have trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Verastem earned a news impact score of 0.9 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Verastem.

Which major investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., AJ Wealth Strategies LLC, Renaissance Technologies LLC, Bank of New York Mellon Corp, Northern Trust Corp and SeaCrest Wealth Management LLC. View Insider Buying and Selling for Verastem.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $1.34.

How big of a company is Verastem?

Verastem has a market capitalization of $99.35 million and generates $26.72 million in revenue each year. The biopharmaceutical company earns $-72,430,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Verastem employs 169 workers across the globe.View Additional Information About Verastem.

MarketBeat Community Rating for Verastem (NASDAQ VSTM)

MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.